The data gathered by researchers during a clinical trial might be sufficient to garner a regulatory approval, but it does not provide sponsor companies with a holistic view of how the drug will perform when made available to the general public. The small number of patients participating in trials, coupled with the lack of diversity present in those populations, makes it difficult to understand all of the effects a treatment will have in patients.
For that reason, real-world evidence (RWE) has been gaining in popularity. In this eBook, we take a close look at RWE. What is it, how is it being used, why all the hype over it, and how the use of RWE is bringing together the worlds of pharma R&D and healthcare. But more importantly, how can we best tap into the data we have available to us today to improve clinical studies and healthcare in the future. Our experts include executives from Bristol-Myers Squibb, Pfizer, the University of Southern California, and Harvard Medical School.